Source - SMW
Hutchison China MediTech  has reported preliminary clinical activity, safety, and tolerability data of fruquintinib, an investigational selective inhibitor of vascular endothelial growth factor receptor given in combination with Iressa.

 Chi-Med said these data were from an ongoing phase II proof-of-concept trial conducted in patients with epidermal growth factor receptor mutation-positive  non-small cell lung cancer. 

It said preliminary data from this phase II proof-of-concept trial, the first study assessing combining fruquintinib with another tyrosine kinase inhibitor, demonstrated promising efficacy and an acceptable safety profile. 

The data were presented at the International Association for the Study of Lung Cancer 18th World Conference on Lung Cancer  in Yokohama, Japan.


At 9:05am: (LON:HCM) Hutchison China Meditech Ltd share price was +50p at 4530p